問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Thoracic Medicine

更新時間：2023-09-19

梁深怡
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

3Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

梁深怡

List

20Cases

2025-06-01 - 2028-12-31

Active
A multicenter, parallel-group, phase 2b, randomized, double-blind, placebo-controlled, 4-group, 24-week trial evaluating the efficacy and safety of AZD6793 tablets in adult subjects with moderate to very severe chronic obstructive pulmonary disease (PRESTO).

  • Condition/Disease

    Evaluate the effect of AZD6793 compared to placebo on the rate of exacerbations in moderate or severe COPD.

  • Test Drug

    AZD6793

Participate Sites
10Sites

Recruiting10Sites

2026-06-01 - 2028-12-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting1Sites

2020-09-15 - 2025-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting6Sites

Terminated6Sites

2009-07-01 - 2010-07-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2012-05-30 - 2013-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2013-07-01 - 2015-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2010-08-30 - 2012-09-30

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2020-06-20 - 2027-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Not yet recruiting3Sites

Recruiting9Sites

Terminated1Sites

2011-09-29 - 2013-12-16

Phase II

A Phase 1-2 trial of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    MM-121(SAR256212)

Participate Sites
6Sites

Terminated6Sites

2012-05-01 - 2014-12-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB